VIP: Safety Profile & Research Summary
$47.25 · Água BAC grátis + frete grátis nos EUA · Despacho no mesmo dia antes das 14h ET · APENAS PARA USO EM PESQUISA
Comprar peptídeo VIP 10mg28 Citacoes PubMedRevisado por EspecialistasUltima Revisao: fevereiro de 2026
Estudos em Animais
- Parkinson’s Disease (Rats, Mosley 2019): VIPR2 agonist LBT-3627 at 2.0 mg/kg — 43% increase in surviving TH+ neurons (α-Syn model), 53% spared at 6.0 mg/kg (6-OHDA model), 57–61% reduction in reactive microglia. [19]
- Parkinson’s Disease (Mice, Delgado 2003): VIP in MPTP model preveniu dopaminergic neuronal loss and microglial ativacao; bloqueou iNOS, IL-1β, TNF-α expression. [21]
- IBD/Colitis (Mice, Jayawardena 2017): VIP-SSM dose unica reversed severe DSS colitis (P<0.0001 vs DSS); restaurou occludin and DRA expression. Free VIP required alternate-day dosing. [22]
- PET Imaging (Mice, Zhang 2007/2008): ⁶⁴Cu-VIP analogues in breast/prostate xenografts — tumor:normal uptake ratios 2.17–10.93, >85% ⁶⁴Cu retention in blood. Detected grade IV prostate neoplasia undetectable by FDG-PET. [23]
- Diabetes (Rats, Tsutsumi 2002): VPAC2 agonist BAY 55-9837 estimulou dependente de glicose secrecao de insulina sem hipoglicemia. [13]
- Cardiovascular tolerability (Dogs, Mosley 2019): LBT-3627 at 0.14–1.4 mg/kg — transient hemodynamic effects apenas at doses >experimental threshold; resolved within 4 hours. [19]
- SCN Circadian (Mice, Kudo 2013): 1 µM VIP aumentou SCN neuronal firing rate (P<0.05), persisting 4–6 hours post-washout. Requires PER1 and Kv3 channels. [16]
Ensaios Clinicos em Humanos
- COVID-19 ARDS Phase 2b/3 (NCT04311697, n=196): 3-day design. Failed desfecho primario; survival and IL-6 secondary endpoints are reported in the cited reference. [4]
- TESICO (NCT04843761, n=461): Aviptadil for COVID-19 hypoxemic respiratory failure. Stopped for futility. [20]
- COVID-19 Phase II (NCT04844580, n=80): 5-day design. Failed primary (hospital discharge); dyspnea and CT-score secondary endpoints reported. [27]
- Sarcoidosis Phase II (n=20): 4-week design. BAL TNF-α and Treg endpoints reported. [25]
- Pulmonary Hypertension (n=20): PA-pressure and cardiac-output endpoints reported. [7]
- Tumor Imaging (Various): ¹²³I-VIP and Tc-99m-TP3654. Detection-rate endpoints reported for primary colorectal tumors and lymph-node metastases. [23]
Status Regulatorio
FDA: Composto Orfao Designation (ARDS, pulmonar hipertensao, sarcoidosis); Fast Track Designation (critical COVID-19).
EMA: Composto Orfao Designation (ARDS, sarcoidosis).
CDSCO (India): registered for emergency use in COVID-19 ARDS (2022).
Perfil de tolerabilidade relatado: Clinical tolerability data are summarised in the cited literature. [4] Handle with standard laboratory PPE. Consult the SDS.
TODOS OS ARTIGOS E INFORMAÇÕES SOBRE PRODUTOS FORNECIDOS NESTE SITE SÃO APENAS PARA FINS INFORMATIVOS E EDUCACIONAIS.
Aviso sobre Estudos In Vitro / Pré-clínicos: Os achados de pesquisa descritos acima foram observados em estudos laboratoriais (in vitro) e/ou em modelos animais. Esses resultados podem não se traduzir em desfechos humanos. Nenhuma alegação é feita em relação a aplicações terapêuticas humanas.
Apenas para Uso Educacional: Este conteúdo resume a literatura laboratorial e clínica publicada apenas para referência de pesquisa. Não é aconselhamento médico.
Editorial Research Note
“Estudos em Animais Parkinson’s Disease (Rats, Mosley 2019): VIPR2 agonist LBT-3627 at 2.0 mg/kg — 43% increase in surviving TH+ neurons (α-Syn model), 53% spared at 6.0 mg/kg (6-OHDA model), 57–61% reduction in reactive microglia.”
Referencias
- Said SI, Mutt V. Polypeptide with broad biological activity: isolation from pequeno(a) intestine. Science, 169(3951), 1217–1218, 1970.
- Said SI, Rosenberg RN. Vasoactive intestinal polypeptide: abundant immunoreactivity in neuronal cell lines and normal nervous tissues. Science, 192(4242), 907–908, 1976.
- Langer I, Jeandriens J, Couvineau A, et al. Signal transduction by VIP and PACAP receptors. Biochem Soc Trans, 50(1), 2022.
- Youssef JG, Lavin P, Schoenfeld DA, et al. Crit Care Med, 50(11), 1545–1554, 2022.
- Domschke S, Domschke W, Bloom SR, et al. Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects. Gut, 19(11), 1049–1053, 1978.
- Harmar AJ, Arimura A, Gozes I, et al. International union of pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev, 50(2), 265–270, 1998.
- Leuchte HH, Baezner C, Baumgartner RA, et al. Eur Respir J, 32(5), 1289–1294, 2008.
- Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulacao. Pharmacol Rev, 56(2), 249–290, 2004.
- Couvineau A, Laburthe M. VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins. Br J Pharmacol, 166(1), 42–50, 2012.
- Hou X, Yang H, Bhatt VR, et al. VIP/VPAC signaling in pancreatic islet β-cells and glucose homeostasis. J Mol Endocrinol, 68(3), R65–R75, 2022.
- Smalley SG, Barrow PA, Foster N. Immunomodulacao of innate resposta imunologicas by vasoactive intestinal peptide (VIP): its experimental potential in inflammatory disease. Clin Exp Immunol, 157(2), 225–234, 2009.
- Constantin S, Bhattarai JP, Bhatt R, et al. VIP signaling in GnRH neurons envolve dual Gs/AC and Gq/PLC pathways. J Neuroendocrinol, 36(4), e13392, 2024.
- Hou X, et al. VIP/VPAC signaling in pancreatic islet β-cells: PKA and Epac pathways drive dependente de glicose secrecao de insulina. J Mol Endocrinol, 2022.
- Moody TW, Nuche-Berenguer B, Jensen RT. Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, e seus(suas) receptors and cancer. Curr Opin Endocrinol Diabetes Obes, 23(1), 38–47, 2016.
- Mathioudakis AG, Chatzimavridou-Grigoriadou V, Evangelopoulou E, Mathioudakis GA. Hippokratia, 17(1), 12–16, 2013.
- Kudo T, Tahara Y, Gamble KL, et al. Vasoactive intestinal peptide produz long-lasting changes in neural activity no(a) suprachiasmatic nucleus. J Neurophysiol, 110(5), 1097–1106, 2013.
- Said SI. Vasoactive intestinal peptide no(a) lung. Ann N Y Acad Sci, 527, 450–464, 1988.
- An S, Tsai C, Bhatt R, et al. Vasoactive intestinal polypeptide phase-shifts the circadian clock via cAMP/PKA dependent pathway. J Biol Rhythms, 26(4), 313–326, 2011.
- Mosley RL, Lu Y, Olson KE, et al. Front Cell Neurosci, 13, 421, 2019.
- Brown SM, Barkauskas CE, Grund B, et al. Lancet Respir Med, 11(9), 791–803, 2023.
- Delgado M, Ganea D. FASEB J, 17(8), 944–946, 2003.
- Jayawardena D, Guzman G, Gill RK, et al. Expression and localization of VPAC1, o(a) principal receptor of vasoactive intestinal peptide along the length do(a) intestine. Am J Physiol Gastrointest Liver Physiol, 313(1), G16–G25, 2017.
- Virgolini I, Raderer M, Kurtaran A, et al. Vasoactive intestinal peptide-receptor imaging para o(a) localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med, 331, 1116–1121, 1994.
- Zhang K, Aruva MR, Shanthly N, et al. PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer. J Nucl Med, 49(1), 112–121, 2008.
- Prasse A, Zissel G, Lützen N, et al. Am J Respir Crit Care Med, 182(4), 540–548, 2010.
- Youssef JG, Said SI, et al. Preprints, 2020.
- Esendagli D, Sarı N, Akhan S, et al. Med Princ Pract, 34(2), 191–200, 2025.
- Dewan B, Shinde S. Eur J Pharm Med Res, 9(6), 243–253, 2022.
Perguntas de Pesquisa Relacionadas
Related research
Browse all research guides in the Peptide Research Library →Deseja a revisao completa da pesquisa?
Comprar peptídeo VIP 10mg→APENAS PARA USO EM PESQUISA
Este conteudo e fornecido apenas para fins educacionais e informativos. Os produtos sao fornecidos apenas para estudos in vitro e nao sao medicamentos, drogas ou suplementos. Nao aprovado pela FDA para prevenir, tratar ou curar qualquer condicao.